阿曼塔丁治疗多发性硬化症相关的疲劳:随机对照试验的系统审查和元分析
Murilo Marmori Cruccioli1, Pedro Henrique Teixeira Carneiro2, Jorge Ferreira Jasmineiro Pitanga3
1Department of Medicine, Universidade Evangélica de Goiás, Anápolis, Brazil.
Neurodegenerative disease management
|December 25, 2025
概括
阿曼塔丁不能有效地减少多发性硬化症 (MS) 患者的疲劳,并增加失眠风险. 本系统性审查质疑其作为MS相关疲劳的第一线治疗方法的使用.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 系统审查是系统的审查.
背景情况:
- 疲劳影响多发性硬化症 (MS) 患者多达95%,严重影响日常功能.
- 阿曼塔丁通常用于MS相关的疲劳,尽管证据有限,并且缺乏FDA对此表示的批准.
- 这项研究系统地审查和分析了阿曼塔丁在治疗MS相关疲劳方面的疗效.
研究的目的:
- 评估阿曼塔丁在减少多发性硬化症患者疲劳严重性的有效性.
- 评估与MS患者使用阿曼塔丁相关的不良反应,特别是失眠的发生率.
主要方法:
- 在MEDLINE,EMBASE和Web of Science进行了对随机对照试验 (RCT) 的系统文献搜索.
- 在分析中包括了9个涉及601名患者的RCT.
- 统计分析,包括标准化平均差异 (SMDs) 和几率比率 (ORs) 具有95%的置信区间 (CI),使用随机效应模型进行.
主要成果:
- 与安慰剂相比,阿曼塔丁治疗没有显著减少疲劳严重程度 (SMD -0.22; p=0.37).
- 与安慰剂 (OR=2.33;p=0.006) 相比,接受阿曼塔丁的患者出现失眠的几率明显更高.
结论:
- 分析表明,阿曼塔丁在治疗多发性硬化症疲劳方面无效.
- 阿曼塔丁的使用与副作用的风险增加有关,特别是失眠.
- 这些发现挑战了当前使用阿曼塔丁作为MS相关疲劳的第一线药理选择的做法.
相关概念视频
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:21Fatigue
Fatigue occurs when materials rupture under repeated or fluctuating loads, even at stress levels far below their static breaking strength. It typically results in brittle failure, even for ductile materials. It is a critical consideration in designing machines and structural components subjected to repetitive or varying loads. The nature of these loadings can range from fluctuating loads like unbalanced pump impellers causing vibrations to repeatedly bending a thin steel rod wire back and forth...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...